KRYS
Price
$147.68
Change
-$2.47 (-1.65%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
4.34B
24 days until earnings call
REGN
Price
$542.37
Change
-$7.63 (-1.39%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
59.38B
14 days until earnings call
Interact to see
Advertisement

KRYS vs REGN

Header iconKRYS vs REGN Comparison
Open Charts KRYS vs REGNBanner chart's image
Krystal Biotech
Price$147.68
Change-$2.47 (-1.65%)
Volume$3.6K
Capitalization4.34B
Regeneron Pharmaceuticals
Price$542.37
Change-$7.63 (-1.39%)
Volume$21.82K
Capitalization59.38B
KRYS vs REGN Comparison Chart in %
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. REGN commentary
Jul 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and REGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 19, 2025
Stock price -- (KRYS: $150.15 vs. REGN: $550.00)
Brand notoriety: KRYS: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 75% vs. REGN: 80%
Market capitalization -- KRYS: $4.34B vs. REGN: $59.38B
KRYS [@Biotechnology] is valued at $4.34B. REGN’s [@Biotechnology] market capitalization is $59.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, both KRYS and REGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 5 bullish, 3 bearish.
  • REGN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both KRYS and REGN are a good buy in the short-term.

Price Growth

KRYS (@Biotechnology) experienced а +0.27% price change this week, while REGN (@Biotechnology) price change was -1.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 10, 2025.

REGN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($59.4B) has a higher market cap than KRYS($4.34B). KRYS has higher P/E ratio than REGN: KRYS (36.01) vs REGN (13.98). KRYS YTD gains are higher at: -4.156 vs. REGN (-22.575). REGN has higher annual earnings (EBITDA): 5.53B vs. KRYS (140M). REGN has more cash in the bank: 8.35B vs. KRYS (617M). KRYS has less debt than REGN: KRYS (9.66M) vs REGN (2.71B). REGN has higher revenues than KRYS: REGN (14.1B) vs KRYS (333M).
KRYSREGNKRYS / REGN
Capitalization4.34B59.4B7%
EBITDA140M5.53B3%
Gain YTD-4.156-22.57518%
P/E Ratio36.0113.98258%
Revenue333M14.1B2%
Total Cash617M8.35B7%
Total Debt9.66M2.71B0%
FUNDAMENTALS RATINGS
KRYS vs REGN: Fundamental Ratings
KRYS
REGN
OUTLOOK RATING
1..100
2016
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
36100
SMR RATING
1..100
5753
PRICE GROWTH RATING
1..100
5863
P/E GROWTH RATING
1..100
9797
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (4) in the Biotechnology industry is significantly better than the same rating for KRYS (70) in the Pharmaceuticals Major industry. This means that REGN’s stock grew significantly faster than KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's SMR Rating (53) in the Biotechnology industry is in the same range as KRYS (57) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as REGN (63) in the Biotechnology industry. This means that KRYS’s stock grew similarly to REGN’s over the last 12 months.

KRYS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as REGN (97) in the Biotechnology industry. This means that KRYS’s stock grew similarly to REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSREGN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
34%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
56%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
63%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 5 days ago
60%
Declines
ODDS (%)
Bearish Trend 19 days ago
75%
Bearish Trend 3 days ago
56%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
42%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCRFX14.960.08
+0.57%
BlackRock Mid-Cap Value Investor C
FIRIX10.14N/A
N/A
Fidelity Advisor Intl Real Estate I
USPCX29.79N/A
N/A
Union Street Partners Value C
JHTAX19.77N/A
N/A
JPMorgan Hedged Equity 3 A
HCAIX111.45N/A
N/A
Harbor Capital Appreciation Inv

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+0.05%
XNCR - KRYS
56%
Loosely correlated
+2.72%
IDYA - KRYS
56%
Loosely correlated
-0.27%
CRNX - KRYS
56%
Loosely correlated
+3.51%
ACLX - KRYS
56%
Loosely correlated
+0.35%
CGON - KRYS
54%
Loosely correlated
+9.13%
More